Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 11:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2833–2856 of 4,253 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Study Product Clear all

Conditions: Spinal Cord Injury, Osteoporosis
Interventions: Fosamax, Placebo; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 100 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Rochester, New York

Conditions: Obesity, Type 2 Diabetes Mellitus
Interventions: MCT oil hypocaloric liquid diet, LCT hypocaloric liquid diet, Subcutaneous abdominal adipose tissue biopsy; Behavioral · Procedure
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Sclerosis
Interventions: Study Drug, Active Control, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Asthma
Interventions: Fenzian Device, Sham Device; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 12 Years to 80 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 3
States / cities: Los Angeles, California • Baltimore, Maryland • Durham, North Carolina

Conditions: Allergic Asthma, Atopic Dermatitis, Allergic Rhinitis, Healthy Volunteers
Interventions: Placebo, Omalizumab, MEDI4212 5 mg Subcutaneous, MEDI4212 15 mg Subcutaneous, MEDI4212 60 mg Subcutaneous, MEDI4212 150 mg Subcutaneous, MEDI4212 300 mg Subcutaneous, MEDI4212 300 mg Intravenous; Other · Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 295 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 7
States / cities: Cypress, California • Glendale, California • Denver, Colorado + 4 more

Conditions: Healthy Volunteers
Interventions: GSBR-1290, Placebo; Drug · Other
Lead sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Second-degree Burn
Interventions: Mepilex Ag (burn dressing), Xeroform Dressing; Device
Lead sponsor: Wayne State University; Other
Eligibility: 7 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Diabetes Mellitus Type 2
Interventions: PF-07081532, Placebo, Clopidogrel; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Anaheim, California • South Miami, Florida

Conditions: HIV Infections
Interventions: Tetanus Toxoid Vaccine, Hepatitis A Vaccine (Inactivated), HIV-1 Immunogen, Hepatitis B Vaccine (Recombinant); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 2
States / cities: Iowa City, Iowa • New York, New York

Conditions: Opioid Dependency
Interventions: Probuphine (buprenorphine implant), placebo implant, Buprenorphine; Drug
Lead sponsor: Titan Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 20
States / cities: Los Angeles, California • National City, California • Oceanside, California + 16 more

Conditions: Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease
Interventions: ATV-1601, Placebo; Drug
Lead sponsor: Atavistik Bio, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 9
States / cities: Phoenix, Arizona • San Diego, California • Augusta, Georgia + 6 more

Conditions: Tinea Pedis
Interventions: S2G6T-1, S2G6T-2, S2G6T-3, S2G6T-4; Drug
Lead sponsor: Sol-Gel Technologies, Ltd.; Industry
Eligibility: 12 Years and older
Enrollment: 283 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 19
States / cities: San Diego, California • Clearwater, Florida • North Miami Beach, Florida + 15 more

Conditions: Adjunctive Treatment of Major Depressive Disorder
Interventions: Pimavanserin, Placebo; Drug · Other
Lead sponsor: ACADIA Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 36
States / cities: Birmingham, Alabama • Rogers, Arkansas • Garden Grove, California + 31 more

Conditions: Graves' Disease
Interventions: IMVT-1402, Placebo; Drug
Lead sponsor: Immunovant Sciences GmbH; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 64
States / cities: Phoenix, Arizona • Huntington Beach, California • Los Angeles, California + 53 more

Conditions: Smallpox
Interventions: Tecovirimat, Smallpox and Mpox Vaccine, Placebo; Drug · Other
Lead sponsor: SIGA Technologies; Industry
Eligibility: 18 Years to 42 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Omaha, Nebraska • Columbus, Ohio

Conditions: Postoperative Urinary Tract Infection
Interventions: Tamsulosin, Control Group; Drug · Other
Lead sponsor: Emory University; Other
Eligibility: 50 Years and older · Male only
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Atlanta, Georgia • Johns Creek, Georgia

Conditions: Ischemic Heart Disease
Interventions: umbilical cord-derived mesenchymal stromal cells (UC-MSCs); Biological
Lead sponsor: Roberto Bolli; Other
Eligibility: 21 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 3
States / cities: Miami, Florida • Louisville, Kentucky • Houston, Texas

Conditions: Post-surgical Pain
Interventions: CA-008, Placebo, Ketorolac, Acetaminophen, Oxycodone, Bupivacaine Hydrochloride; Drug
Lead sponsor: Concentric Analgesics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 3
States / cities: Pasadena, California • Pasadena, Maryland • Houston, Texas

Conditions: Hip Osteoarthritis, Hip Impingement Syndrome, Cartilage Damage, Fibrosis
Interventions: Losartan, Placebo; Drug · Other
Lead sponsor: Steadman Philippon Research Institute; Other
Eligibility: 18 Years to 60 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Vail, Colorado

Conditions: Blepharitis
Interventions: KPI-121, Vehicle; Drug
Lead sponsor: Kala Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 8
States / cities: Birmingham, Alabama • Artesia, California • Mission Hills, California + 5 more

Conditions: Non-alcoholic Steatohepatitis
Interventions: MGL-3196, Placebo; Drug
Lead sponsor: Madrigal Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 26
States / cities: Dothan, Alabama • Tucson, Arizona • Coronado, California + 23 more

Conditions: Periarticular Block, Osteoarthritis (OA), Osteoarthritis (OA) of the Knee, Pain After Surgery, Knee Arthroplasty, Total
Interventions: bupivacaine-meloxicam (extended release), Bupivacaine, Ketorolac, Lidocaine (drug); Combination Product · Drug
Lead sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute); Other
Eligibility: 18 Years to 89 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Cranberry Township, Pennsylvania

Conditions: Hypercholesterolemia
Interventions: Evolocumab, Placebo, Atorvastatin, Ezetimibe, Diet Only; Biological · Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 905 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 41
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 33 more

Conditions: Hepatitis C, Chronic
Interventions: Tegobuvir (GS-9190), GS-9451, Pegasys®, Copegus®, Tegobuvir placebo, GS-9451 placebo; Drug · Biological
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 85
States / cities: Dothan, Alabama • Montgomery, Alabama • Phoenix, Arizona + 62 more

Search by objective public record fields.

Pilot Study of Fosamax in Spinal Cord Injury

Use of MCT Oil for Enhancement of Weight Loss and Glycemic Control in Obese Diabetic Patients

A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults

Fenzian Asthma Multicenter Outcomes Study

A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL

A Study of Multiple Ascending Doses of GSBR-1290 in Japanese and Non-Japanese Healthy Participants

Mepilex Ag vs. Xeroform in Pediatric Patients That Sustain Partial Thickness Burn Injury

Multiple Escalating Oral Doses Study of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus

A Study to Test If Giving Remune (an HIV Vaccine) Can Improve the Immune Systems of HIV-Positive Patients Who Are Also Participating in ACTG 328

A Six-Month Randomized Controlled Trial (RCT) of Probuphine Safety and Efficacy in Opioid Addiction

Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)

Efficacy and Safety of Product S2G6T-1in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis

Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS

Function of Tamsulosin in Older Males Undergoing Surgery With Indwelling Catheter

Single or Repeated Intravenous Administration of umbiliCAl Cord Mesenchymal sTrOmal Cells in Ischemic Cardiomyopathy

Study of CA-008 (Vocacapsaicin) in Bunionectomy Patients

Losartan to Improve Hip Microfracture

Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease

Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)

Post-Operative Pain Relief: Zynrelef or Periarticular Injections in RATKA

Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study

A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C